FibroGen's GAAP loss for 2021 was $290.023 million, up 53.2% from $189.291 million in the prior year. Revenue increased 33.5% to $235.309 million from $176.319 million a year earlier.
FibroGen's GAAP loss for 2021 was $290.023 million, up 53.2% from $189.291 million in the prior year. Revenue increased 33.5% to $235.309 million from $176.319 million a year earlier. 
fibrogen.gcs-web.com
English (US) 